513 related articles for article (PubMed ID: 30617129)
1. Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
Chen X; Chang CW; Spoerke JM; Yoh KE; Kapoor V; Baudo C; Aimi J; Yu M; Liang-Chu MMY; Suttmann R; Huw LY; Gendreau S; Cummings C; Lackner MR
Clin Cancer Res; 2019 Apr; 25(7):2254-2263. PubMed ID: 30617129
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228
[TBL] [Abstract][Full Text] [Related]
3. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments.
Wang Y; Zhou K; Wang X; Liu Y; Guo D; Bian Z; Su L; Liu K; Gu X; Guo X; Wang L; Zhang H; Tao K; Xing J
Cancer Sci; 2021 Nov; 112(11):4772-4784. PubMed ID: 34490703
[TBL] [Abstract][Full Text] [Related]
4. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
5. Copy number variation in plasma as a tool for lung cancer prediction using Extreme Gradient Boosting (XGBoost) classifier.
Yu D; Liu Z; Su C; Han Y; Duan X; Zhang R; Liu X; Yang Y; Xu S
Thorac Cancer; 2020 Jan; 11(1):95-102. PubMed ID: 31694073
[TBL] [Abstract][Full Text] [Related]
6. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
[TBL] [Abstract][Full Text] [Related]
7. Unbiased Detection of Somatic Copy Number Aberrations in cfDNA of Lung Cancer Cases and High-Risk Controls with Low Coverage Whole Genome Sequencing.
Taylor F; Bradford J; Woll PJ; Teare D; Cox A
Adv Exp Med Biol; 2016; 924():29-32. PubMed ID: 27753014
[TBL] [Abstract][Full Text] [Related]
8. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
9. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis.
Wei T; Zhang J; Li J; Chen Q; Zhi X; Tao W; Ma J; Yang J; Lou Y; Ma T; Li X; Zhang Q; Chen W; Que R; Gao S; Bai X; Liang T
Mol Oncol; 2020 Sep; 14(9):1966-1977. PubMed ID: 32593194
[TBL] [Abstract][Full Text] [Related]
10. CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients.
Peng H; Lu L; Zhou Z; Liu J; Zhang D; Nan K; Zhao X; Li F; Tian L; Dong H; Yao Y
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31739500
[TBL] [Abstract][Full Text] [Related]
11. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
[TBL] [Abstract][Full Text] [Related]
12. Cell-free DNA copy number variations in plasma from colorectal cancer patients.
Li J; Dittmar RL; Xia S; Zhang H; Du M; Huang CC; Druliner BR; Boardman L; Wang L
Mol Oncol; 2017 Aug; 11(8):1099-1111. PubMed ID: 28504856
[TBL] [Abstract][Full Text] [Related]
13. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
14. Low-Pass Genome Sequencing: Validation and Diagnostic Utility from 409 Clinical Cases of Low-Pass Genome Sequencing for the Detection of Copy Number Variants to Replace Constitutional Microarray.
Chaubey A; Shenoy S; Mathur A; Ma Z; Valencia CA; Reddy Nallamilli BR; Szekeres E; Stansberry L; Liu R; Hegde MR
J Mol Diagn; 2020 Jun; 22(6):823-840. PubMed ID: 32344035
[TBL] [Abstract][Full Text] [Related]
15. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
[TBL] [Abstract][Full Text] [Related]
17. Comparison of commercially available whole-genome sequencing kits for variant detection in circulating cell-free DNA.
Mauger F; Horgues C; Pierre-Jean M; Oussada N; Mesrob L; Deleuze JF
Sci Rep; 2020 Apr; 10(1):6190. PubMed ID: 32277101
[TBL] [Abstract][Full Text] [Related]
18. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
[TBL] [Abstract][Full Text] [Related]
19. Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.
Jiang T; Jiang L; Dong X; Gu K; Pan Y; Shi Q; Zhang G; Wang H; Zhang X; Yang N; Li Y; Xiong J; Yi T; Peng M; Song Y; Fan Y; Cui J; Chen G; Tan W; Zang A; Guo Q; Zhao G; Wang Z; He J; Yao W; Wu X; Chen K; Hu X; Hu C; Yue L; Jiang D; Wang G; Liu J; Yu G; Li J; Zhang H; Wu L; Fang L; Liang D; Zhao Y; Zhao W; Xie W; Ren S; Zhou C
Theranostics; 2021; 11(1):257-267. PubMed ID: 33391473
[No Abstract] [Full Text] [Related]
20. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
Stover DG; Parsons HA; Ha G; Freeman SS; Barry WT; Guo H; Choudhury AD; Gydush G; Reed SC; Rhoades J; Rotem D; Hughes ME; Dillon DA; Partridge AH; Wagle N; Krop IE; Getz G; Golub TR; Love JC; Winer EP; Tolaney SM; Lin NU; Adalsteinsson VA
J Clin Oncol; 2018 Feb; 36(6):543-553. PubMed ID: 29298117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
